CVS Stock Price Today (October 2026) — CVS Health Corporation Analysis & Key Metrics 2026-10-20
CVS Health Corporation (CVS) is trading at $94.75, up 2.23% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $115.48 (21.9% upside).
- Volatility is low (19.69% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (7.10% YoY) alongside competitive pressures in the Healthcare Plans space.
CVS Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
CVS Health Corporation - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $183.53B
P/E Ratio
Forward P/E: 11.04
Revenue Growth
Year over Year
Analyst Target
+21.9% upside potential
Key Investor Questions About CVS
What investors need to know before buying
Based on current market data, CVS presents a overbought technical setup with looking solid fundamentals.
- Technicals say: Overbought (RSI 71.26)
- Fundamentals say: Looking solid (debt and growth supportive)
CVS's growth trajectory depends on its ability to expand within the Healthcare Plans sector while managing margin pressures.
- Future growth will depend on performance in core Healthcare Plans operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for CVS investors include debt exposure and competitive dynamics in the Healthcare Plans industry.
- $76.31B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Healthcare Plans.
52-Week Trading Range
Over the past year, CVS stock traded between $69.51 and $110.68 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 19.69% annualized volatility and β=0.08, the stock exhibits low sensitivity to market moves—making CVS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
CVS targets former Walgreens, Rite Aid customers after 1,000 stores close
Alaska Airlines taps CVS Health exec for newly created tech role
How CVS' Aetna Is Advancing Efforts to Reduce Administrative Burden
MinuteClinic® opens three new retail medical clinics to serve Massachusetts patients
CVS Health Collaborates With the Midlife Collective To Redefine a Woman’s Midlife Health Journey
Latest TickZen Insights
All insights →No TickZen article on CVS yet. Our newest analysis:
Explore More Analysis for CVS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 4, 2026 (before the open)
Frequently Asked Questions
Common investor questions about CVS Health Corporation
CVS Health Corporation (CVS) is currently trading at $94.75. The RSI (14-day) is at 71.3, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $115.48 implies 21.9% upside from current levels. Volatility is low at 19.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for CVS Health Corporation (CVS): The trailing P/E ratio is 25.21, which is in line with broader market averages. The forward P/E is 11.04, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.25, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 1.53. Price-to-Sales is 0.30. Valuation should be compared to Healthcare Plans industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering CVS, the consensus price target is $115.48. This represents a 21.9% upside from the current price of $94.75. The range spans from a low target of $103.00 to a high target of $145.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, CVS Health Corporation (CVS) pays a dividend with a current yield of approximately 3.04%. The annualized dividend rate is $2.66 per share. The payout ratio is 70.0%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was Oct 22, 2026.
Key risks for CVS Health Corporation (CVS) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Healthcare Plans sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is CVS Health Corporation's (CVS) current debt and financial health profile: Total debt stands at $76.31B. The debt-to-equity ratio is 0.96x, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 0.87, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.62. The company holds $13.96B in cash and equivalents. Free cash flow is positive at $8.08B, providing a cushion for debt servicing and shareholder returns.